Fewer than one in 10 patients eligible to benefit from weight-loss injections including Wegovy have access to them, caution the WHO as it issues its inaugural advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
Per forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be managed with holistic and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are significant hurdles to universal access to the treatments that can help people shift significant body mass, explains the organization.
GLP-1 Therapy Shortage
Despite the present most favorable case, the supply of these medications would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the WHO.
The guideline encourages countries and companies to increase availability, by approaches including licensing agreements.
A patent on the active ingredient – the primary ingredient of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Injections Operate
These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and boost feelings of fullness so people consume fewer calories.
Individuals usually begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence points to patients may regain a significant portion a year later of stopping the treatment, because their usual appetite come back.
To be above a healthy weight elevates your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
